Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

BACKGROUND: Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate the efficacy and safety of apatinib plus icotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Zhang, Xiangru, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648303/
https://www.ncbi.nlm.nih.gov/pubmed/29075129
http://dx.doi.org/10.2147/OTT.S142686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648303/
https://www.ncbi.nlm.nih.gov/pubmed/29075129
http://dx.doi.org/10.2147/OTT.S142686

Ejemplares similares